IN8bio reports progress on clinical programs for gamma-delta T cell therapies, highlighting durable remissions in challenging cancers.
Quiver AI Summary
IN8bio, Inc., a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has reported strong progress in its Phase 1 and Phase 2 clinical programs, showing significant long-term remissions in challenging cancers like glioblastoma and 100% relapse-free rates in Acute Myeloid Leukemia patients. The company announced the launch of its novel INB-600 platform, which focuses on a gamma-delta T cell engager targeting CD19, aimed at enhancing outcomes in oncology and autoimmune conditions. With a strategic focus on optimizing operations and extending its cash runway through fundraising efforts, IN8bio is well-positioned to advance its innovative therapies and achieve key milestones through 2025 and into 2026. Financially, the company reported a net loss of $30.7 million for 2024, alongside a cash position of $11.1 million as of year-end.
Potential Positives
- Ongoing Phase 1 clinical programs demonstrate a 100% relapse-free rate in treated Acute Myeloid Leukemia (AML) patients, indicating strong potential for the INB-100 therapy.
- Introduction of the novel INB-600 platform, which targets CD19, offers a promising advancement in gamma-delta T Cell engager technology for treating oncology and autoimmune diseases.
- The company has successfully strengthened its cash position, raising approximately $16.6 million to support ongoing operations and development through 2026.
- Presented updated data indicating long-term survival benefits in glioblastoma patients receiving INB-200 therapy, showing significant potential for improved patient outcomes.
Potential Negatives
- Enrollment in the Phase 2 INB-400 glioblastoma program has been paused, which could delay potential developments and revenue from this program despite previously reported compelling data.
- The company reported a net loss of $30.7 million for the year, slightly higher than the previous year's loss, raising concerns about its financial sustainability.
- Cash position decreased significantly from $21.3 million in 2023 to $11.1 million in 2024, indicating potential financial strain and a need for additional capital to support ongoing operations and development.
FAQ
What are the key updates in IN8bio's clinical programs?
IN8bio reported ongoing success in Phase 1 and Phase 2 trials, showing durable remissions in glioblastoma and 100% relapse-free rates in AML.
What is the INB-600 platform being developed by IN8bio?
INB-600 is a novel gamma-delta T cell engager targeting CD19, aimed at improving treatment outcomes in oncology and autoimmune diseases.
How is IN8bio managing its financial position?
IN8bio has raised approximately $16.6 million and implemented cost-saving measures to support its operations through 2026.
What are the future milestones for IN8bio's clinical trials?
Upcoming milestones include accelerating patient enrollment for INB-100 and presenting updated clinical data by the second half of 2025.
How did IN8bio's financial performance change in 2024?
IN8bio's net loss for 2024 was $30.7 million, with R&D expenses reflecting increased clinical activities in key programs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$INAB Hedge Fund Activity
We have seen 14 institutional investors add shares of $INAB stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FRANKLIN RESOURCES INC added 5,696,202 shares (+inf%) to their portfolio in Q4 2024, for an estimated $1,465,063
- ALYESKA INVESTMENT GROUP, L.P. added 4,628,482 shares (+1064.5%) to their portfolio in Q4 2024, for an estimated $1,190,445
- AIGH CAPITAL MANAGEMENT LLC added 4,517,227 shares (+269.7%) to their portfolio in Q4 2024, for an estimated $1,161,830
- ENSIGN PEAK ADVISORS, INC removed 829,176 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $213,264
- 683 CAPITAL MANAGEMENT, LLC removed 600,304 shares (-44.5%) from their portfolio in Q4 2024, for an estimated $154,398
- SIGMA PLANNING CORP added 190,100 shares (+22.3%) to their portfolio in Q4 2024, for an estimated $48,893
- GEODE CAPITAL MANAGEMENT, LLC added 185,919 shares (+56.5%) to their portfolio in Q4 2024, for an estimated $47,818
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including
glioblastoma (GBM) and
100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free
Expanded pipeline with INB-600 platform, featuring novel gamma-delta T Cell engager (TCE)
targeting CD19
for potential use in oncology and autoimmune diseases
Continued operational execution with strengthened strategic focus on aligning resources in an effort to drive high-impact programs forward
Maintaining cash position to support operations and achievement of anticipated development milestones throughout 2025 and into 2026
NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) --
IN8bio, Inc
. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2024.
William Ho, Chief Executive Officer and co-founder of IN8bio, commented, “In 2024, IN8bio made significant progress advancing its pipeline of gamma-delta T cell therapies and positioning the Company for long-term success. The INB-100 program continues to demonstrate 100% long term durable response rates as of January 17, 2025, reinforcing its potential to help treat and maintain remissions in high-risk AML patients.” Mr. Ho continued, “We have also disclosed our novel INB-600 platform, which we believe has the potential to reshape the T cell engager landscape by potentially improving both the durability of response and safety compared to existing CD3 targeting TCE therapies. Throughout 2025, we remain focused on driving innovation, advancing our clinical programs and delivering value to patients and our stakeholders.”
Key Highlights
Announced INB-600 Platform & INB-619, a Novel Preclinical Gamma-Delta TCE
Introduced INB-619, a proprietary next generation gamma-delta TCE targeting CD19 for potential use in oncology and autoimmune diseases (March 2025)
Demonstrated potent B-cell depletion and sustained gamma-delta T cell expansion in preclinical studies, offering commercial and scientific advantages by potentially improving durability and safety over existing CD3 targeting TCE therapies
Demonstrated Additional Clinical Progress with INB-100
(Allogeneic Gamma-Delta T Cell Therapy for AML & Leukemias)
for High-Risk AML
Presented new Phase 1 data
showing durable remissions with 100% of treated AML patients remaining relapse-free (February 2025)
Observed favorable safety profile with no cytokine release syndrome (CRS) or neurotoxicity (ICANs) reported to date
Presented expanded clinical data at 2025 Tandem Meetings reinforcing potential of INB-100 to significantly reduce post-transplant relapse in high-risk AML patients relative to historical real-world data
Presented Continued Durable Remissions in Phase 1 Trial of INB-200 (Autologous, Drug-Resistant Gamma-Delta T Cell Therapy for Glioblastoma)
Presented updated data in a plenary oral presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting, showing
the majority of patients
exceeded their expected progression free survival based on age and tumor status
Highlighted potential long-term benefits of INB-200. As of October 18, 2024, five patients remained alive, three patients had returned to work, and one IDH-mutant, grade 4 glioma patient remained progression free for an impressive 40.5 months post treatment
Strategically Optimized Pipeline and Launched Operational Efficiency Initiatives
Paused enrollment in the Phase 2 INB-400 glioblastoma program – despite compelling data – to focus resources while exploring partnership and alternative funding opportunities
Implemented cost-saving measures to extend cash runway and prioritize pipeline development
Raised approximately $16.6 million in gross proceeds through various equity offerings, including through our at-the-market (“ATM”) offering program and private placements, during 2024 through February 2025, extending the Company’s cash runway into March 2026
Upcoming Anticipated Pipeline Milestones and Important Events
INB-100: For the potential treatment of high-risk leukemias including AML
Accelerating patient enrollment in expansion cohort of ongoing Phase 1 clinical trial including the inclusion of an additional investigational center
Aim to complete enrollment into the expansion cohort in 2025. Guidance from the U.S. Food and Drug Administration (FDA) confirmed relapse-free survival (RFS) in AML patients as an acceptable primary endpoint for a potential pivotal randomized control trial
Expect to present updated clinical data in the second half of 2025
Advancing preparations for potential registrational Phase 2 trial with possible IND submission anticipated in 2026 based on receipt of additional funding
INB-200 and INB-400 (Autologous Gamma-Delta T Cell Therapy for Glioblastoma & Solid Tumors):
Continue to evaluate early clinical data for signs of efficacy and durability
Report additional findings at upcoming medical meetings in 2025
Seek additional funding sources to advance allogeneic product for glioblastoma and other solid tumors
INB-600 and INB-619 (Gamma-Delta T Cell Engager Targeting CD19 – Oncology & Autoimmune Diseases):
Present preclinical data evaluating potency, expansion potential, and safety profile at medical meetings in the second quarter of 2025
Plan to advance towards IND-enabling studies with additional funding to support future clinical development
Exploring partnership and collaboration options to accelerate development of the platform
Fourth Quarter and Full Year 2024 Financial Highlights
Research and Development (R&D) expenses:
R&D expenses were $3.8 million for the three months ended December 31, 2024, compared with $4.5 million for the comparable prior year period. R&D expenses were $17.2 million for the year ended December 31, 2024, compared with $16.8 million in the prior year. The change was primarily due to increased clinical trial-related activities for the INB-100 and INB-400 programs and was partially offset by a decrease in personnel-related costs and facility-related and other expenses, in each case as a result of the Company’s pipeline prioritization announced in September 2024.
General and administrative (G&A) expenses:
G&A expenses were $2.6 million for the three months ended December 31, 2024, compared with $3.1 million for the comparable prior year period. G&A expenses were $12.6 million for the year ended December 31, 2024, compared with $13.5 million in the prior year. The change was primarily due to cost savings related to director and officer insurance premiums, professional services, and personnel-related costs, partially offset by an increase in legal and consulting expenses.
Severance and related charges:
Severance and related charges were $1.1 million for the year ended December 31, 2024, compared with zero in the prior year. These were one-time costs related to the September 2024 workforce reduction, including non-cash stock-based compensation expense and severance payments.
Net loss:
The company reported a net loss of $6.4 million, or $0.08 per basic and diluted common share, for the three months ended December 31, 2024, compared with a net loss of $7.6 million, or $0.22 per basic and diluted common share, for the comparable prior year period. For the year ended December 31, 2024, net loss was $30.7 million, or $0.57 per basic and diluted common share, compared with a net loss of $30.0 million, or $1.00 per basic and diluted common share, for the prior year.
Cash position:
As of December 31, 2024, the Company had cash of $11.1 million as of December 31, 2024, compared with $21.3 million as of December 31, 2023. Subsequently, in February 2025, the Company sold common stock under its ATM offering program and had Series C warrants exercised for aggregate net proceeds of $4.1 million.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-100, is focused on AML evaluating haplo-matched allogeneic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma, and advancing novel gamma-delta TCEs for potential oncology and autoimmune indications. For more information about IN8bio, visit
www.IN8bio.com
.
Forward Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the ability of gamma-delta T cell therapies to continue to exhibit long-term durable remissions in hard-to-treat cancers; IN8bio’s ability to expand pipeline and potential partnership opportunities, including those related to INB-200, INB-400 and INB-600; IN8bio’s ability to drive high-impact programs forward and position for long-term success; the ability of INB-600 to reshape the TCE landscape and to improve durability and safety over existing CD3-targeting TCE therapies; the evaluation of INB-619 in preclinical studies and its applicability for oncology and autoimmune indications; INB-100’s ability to continue to achieve durable remissions in AML patients; IN8bio’s anticipated cash runway; the potential long-term benefits of INB-200; plans to accelerate patient enrollment for INB-100, to complete the expansion cohort in 2025 and to advance preparations for a potential registrational Phase 2 trial; IN8bio’s ability to achieve other anticipated milestones, including expected presentations and data readouts from its trials, enrollment of additional patients in its clinical trials, IND submissions and advancement of clinical development plans; and other statements that are not historical fact. IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as IN8bio’s ability to meet anticipated deadlines and milestones; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio’s product candidates; the risk that IN8bio may be unable to raise additional capital and could be forced to delay, further reduce or to explore other strategic options for certain of our development programs, or even terminate its operations; IN8bio’s ability to continue to operate as a going concern; the risk that IN8bio may not realize the intended benefits of its DeltEx platform; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio’s product candidates; the uncertainty of regulatory approvals to conduct trials or to market products; IN8bio’s reliance on third parties, including licensors and clinical research organizations; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 12, 2024, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
IN8BIO, INC. Balance Sheets (In thousands, except share and per share data) | ||||||||
December 31, | December 31, | |||||||
2024 | 2023 | |||||||
Assets | ||||||||
Current assets | ||||||||
Cash | $ | 11,120 | $ | 21,282 | ||||
Prepaid expenses and other current assets | 1,458 | 3,343 | ||||||
Total Current Assets | 12,578 | 24,625 | ||||||
Non-current assets | ||||||||
Property and equipment, net | 2,858 | 3,514 | ||||||
Construction in progress | — | 182 | ||||||
Restricted cash | 266 | 256 | ||||||
Right-of-use assets - finance leases | 1,068 | 1,364 | ||||||
Right-of-use assets - operating leases | 3,899 | 3,513 | ||||||
Other non-current assets | 275 | 255 | ||||||
Total Non-Current Assets | 8,366 | 9,084 | ||||||
Total Assets | $ | 20,944 | $ | 33,709 | ||||
Liabilities and Stockholders' Equity | ||||||||
Liabilities | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 389 | $ | 924 | ||||
Accrued expenses and other current liabilities | 1,047 | 2,955 | ||||||
Short-term finance lease liability | 694 | 694 | ||||||
Short-term operating lease liability | 953 | 820 | ||||||
Total Current Liabilities | 3,083 | 5,393 | ||||||
Long-term finance lease liability | 295 | 525 | ||||||
Long-term operating lease liability | 3,088 | 2,854 | ||||||
Total Non-Current Liabilities | 3,383 | 3,379 | ||||||
Total Liabilities | 6,466 | 8,772 | ||||||
Commitments and Contingencies | ||||||||
Stockholders' Equity | ||||||||
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized at December 31, 2024 and 2023. No shares issued and outstanding | — | — | ||||||
Common stock, par value $0.0001 per share; 490,000,000 shares authorized at December 31, 2024 and 2023; 72,483,253 and 43,287,325 shares issued and outstanding at December 31, 2024 and 2023, respectively | 7 | 4 | ||||||
Additional paid-in capital | 136,367 | 116,152 | ||||||
Accumulated deficit | (121,896 | ) | (91,219 | ) | ||||
Total Stockholders' Equity | 14,478 | 24,937 | ||||||
Total Liabilities and Stockholders' Equity | $ | 20,944 | $ | 33,709 | ||||
IN8BIO, INC. Statements of Operations (In thousands, except share and per share data) | ||||||||
Year Ended December 31, | ||||||||
2024 | 2023 | |||||||
Operating expenses: | ||||||||
Research and development | $ | 17,202 | $ | 16,827 | ||||
General and administrative | 12,637 | 13,510 | ||||||
Severance and related charges | 1,068 | — | ||||||
Total operating expenses | 30,907 | 30,337 | ||||||
Interest income | 230 | — | ||||||
Other income | — | 330 | ||||||
Loss from operations | (30,677 | ) | (30,007 | ) | ||||
Net loss | $ | (30,677 | ) | $ | (30,007 | ) | ||
Net loss per share – basic and diluted | $ | (0.57 | ) | $ | (1.00 | ) | ||
Weighted-average number of shares used in computing net loss per common share – basic and diluted | 53,547,030 | 29,864,932 | ||||||
Investors & Company Contacts:
Glenn Schulman, PharmD, MPH
203.494.7411
gdschulman@in8bio.com
IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com
Media Contact:
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
